Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2018’, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease)

- The report reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pituitary ACTH Hypersecretion (Cushing Disease) therapeutics and enlists all their major and minor projects

- The report assesses Pituitary ACTH Hypersecretion (Cushing Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Diurnal Group Plc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Diurnal Group Plc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pituitary ACTH Hypersecretion (Cushing Disease) – Overview

Pituitary ACTH Hypersecretion ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pituitary ACTH Hypersecretion (Cushing Disease) – Overview

Pituitary ACTH Hypersecretion (Cushing Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pituitary ACTH Hypersecretion (Cushing Disease) – Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Diurnal Group Plc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease) – Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing’s Syndrome and Cushing Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23B065 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Silibinin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cushing Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide MR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pituitary ACTH Hypersecretion (Cushing Disease) – Dormant Projects

Pituitary ACTH Hypersecretion (Cushing Disease) – Discontinued Products

Pituitary ACTH Hypersecretion (Cushing Disease) – Product Development Milestones

Featured News & Press Releases

Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder

Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation from EMA to Treat Cushing’s Syndrome

Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing’s Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Amryt Pharma plc, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Diurnal Group Plc, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Ipsen SA, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Novartis AG, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Pipeline by Strongbridge Biopharma plc, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Dormant Projects, H1 2018

Pituitary ACTH Hypersecretion (Cushing Disease) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports